Value in Health Regional Issues

Slides:



Advertisements
Similar presentations
Percentage of inpatients by board cause group , Thailand Sources: Individual patient information under the Universal Coverage Scheme, Civil Servant.
Advertisements

Value in Health Regional Issues
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Examining the Value of Menopausal Symptom Relief Among US Women
Value in Health Regional Issues
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
An Audit of Diabetes-Dependent Quality of Life (ADDQOL) in Older Patients with Diabetes Mellitus Type 2 in Slovenia  Eva Turk, MA, MBA, Valentina Prevolnik.
Value in Health Regional Issues
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Value in Health Regional Issues
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Value in Health Regional Issues
Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
From Regulatory Approval to Subsidized Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand,
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan  Kaoru Yamabe, MSc, Puneet K. Singhal,
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
The Process of Privatization of Health Care Provision in Poland
Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
The Living with Medicines Questionnaire: Translation and Cultural Adaptation into the Arabic Context  Amani Zidan, BScPharm, Ahmed Awaisu, PhD, Sanah.
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Value in Health Regional Issues
Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea  Bo-Ra-Mi Kim, MPH, Tae-Jin Lee, PhD,
Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia  Mihajlo Jakovljević, MD, PhD,
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Attributable Cost and Length of Stay for Patients with Enoxaparin-Associated Bleeding  Surasak Saokaew, PharmD, Narinee Khaisombat, MSc, Nathorn Chaiyakunapruk,
Value in Health Regional Issues
Value in Health Regional Issues
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India  S.K.R. Sowmya, PharmD, Dixon.
Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire  Bhavik Shah,
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Omneya Mohamed, PhD, David H. Kreling, PhD 
Patient Utility Measurement for Managing Ureteral Stones: A Modified Standard Gamble Approach  Ching-Yuan Fann, PhD, Po-Chien Huang, MD, MS, Amy Ming-Fang.
Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M
Analysis of Excess Direct Medical Costs of Vision Impairment in Taiwan
Value in Health Regional Issues
Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?  Fei-Li.
A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations  Panagiotis Petrou, MBA, PhD, PhDc, Michalis.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Value in Health Regional Issues
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Drug Utilization Reviews by Community Pharmacists in Japan: Identification of Potential Safety Concerns through the Brown Bag Program  Manabu Akazawa,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Incidence of Intravenous Medication Errors in a Chinese Hospital
Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan  Yoshie Onishi, MS,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Guidance Document: Global Pharmacoeconomic Model Adaption Strategies
Value in Health Regional Issues
Value in Health Regional Issues
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Value in Health Regional Issues
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
The Drug Reimbursement Decision-Making System in Iran
Social Cost of Substance Abuse in Russia
Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries  Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.
Victoria I. Ignatyeva, MPH, Johan L
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Value in Health Regional Issues Comparison of Health Care Utilization and Costs for Patients with Asthma by Severity and Health Insurance in Thailand  Piyameth Dilokthornsakul, PharmD, PhD, Todd A Lee, PharmD, PhD, Teerapon Dhippayom, PharmD, PhD, Napawan Jeanpeerapong, MS, Nathorn Chaiyakunapruk, PharmD, PhD  Value in Health Regional Issues  Volume 9, Pages 105-111 (May 2016) DOI: 10.1016/j.vhri.2016.03.001 Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Figure 1 A flow of patient selection. Value in Health Regional Issues 2016 9, 105-111DOI: (10.1016/j.vhri.2016.03.001) Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Figure 2 Percentages of patients receiving asthma medications by severity of disease and health insurance schemes. CSMBS, Civil Servant Medical Benefit Scheme; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; SSI, Social Security Insurance; UC, Universal Coverage Scheme. *Short-acting beta-agonists included both inhaled and oral forms. Value in Health Regional Issues 2016 9, 105-111DOI: (10.1016/j.vhri.2016.03.001) Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.